Wei Xie

Medicine & Life Sciences

1. Acute Myeloid Leukemia 100%
2. Myelodysplastic Syndromes 50%
3. Lymphoma 45%
4. Second Primary Neoplasms 41%
5. Arterioles 39%
6. Bradykinin 37%
7. Precursor Cell Lymphoblastic Leukemia-Lymphoma 35%
8. Neoplasms 35%
9. Karyotype 35%
10. Exercise 35%
11. Mutation 32%
12. nuclear pore complex protein 98 31%
13. Immunoglobulin lambda-Chains 31%
14. T-Lymphocytes 30%
15. Hematologic Neoplasms 30%
16. Dilatation 30%
17. Swine 28%
18. Systemic Mastocytosis 26%
19. Megakaryocytes 26%
20. Mastocytosis 25%
21. Anaplastic Large-Cell Lymphoma 24%
22. Nitric Oxide Synthase Type III 23%
23. Cytogenetics 23%
24. Chromosomes, Human, Pair 21 23%
25. Polyploidy 22%
26. Non-Hodgkin's Lymphoma 22%
27. Acute Promyelocytic Leukemia 22%
28. Nitric Oxide 21%
29. Lymph Nodes 21%
30. Endothelium 21%
31. Hyperplasia 21%
32. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 20%
33. T-Cell Lymphoma 20%
34. Ascitic Fluid 20%
35. Bone Marrow 20%
36. Survival 19%
37. Bronchoalveolar Lavage 19%
38. Lymphoma, Large B-Cell, Diffuse 18%
39. Superoxides 18%
40. Lymphadenopathy 18%
41. Multiple Myeloma 17%
42. ameroid 17%
43. Critical Illness 16%
44. Natural Killer Cells 16%
45. Flow Cytometry 16%
46. Protein-Tyrosine Kinases 16%
47. Splenomegaly 15%
48. Exons 15%
49. Disease Progression 14%